MAPT and Alzheimer disease: Moreover, since it has long been recognized that pathophysiological changes of AD begin many years before the development of clinical manifestations [13], NIA-AA research framework also proposed to group biomarkers into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)] to create different categories according to biomarkers positivity [14].